Clinician's Roundtable   /     Poster Pearl: Comparing Endorsed vs. Non-Endorsed CRC Screening Tests

Shownotes

Host: Matt Birnholz, MD

The United States Preventative Services Task Force endorses multiple screening options for patients at average-risk of colorectal cancer (CRC). These options include colonoscopy, multi-target stool DNA, and the fecal immunochemical test. However, performance data for non-endorsed options like multi-target stool RNA and blood-based screening tests have recently been published. That’s why a recent poster presented at the 2024 Digestive Disease Week conference compared the benefit-to-harm ratio for guideline-endorsed versus non-endorsed CRC screening tests. Tune in to learn more about the findings and their implications for CRC screening.